Introduction
============

Schizophrenia is a chronic psychiatric disorder characterized by hallucinations, delusions, negative symptoms, and disruptive thoughts and behaviors that typically arise during late adolescence or early adulthood ([@b57-ndt-4-967]). It affects approximately 1% of the US population ([@b48-ndt-4-967]) and is estimated to have a global prevalence of 0.14%--0.46% ([@b23-ndt-4-967]).

The newer, second-generation antipsychotics (SGAs), also referred to as atypical antipsychotics, are thought to represent a significant advance over conventional first-generation antipsychotics (FGAs) in the treatment of patients with schizophrenia. Specifically, SGAs have a lower propensity to cause extra-pyramidal symptoms (EPS) (eg, dystonia, tardive dyskinesia, akathisia and parkinsonism), which limit the safety of and long-term compliance with FGAs ([@b28-ndt-4-967]; [@b46-ndt-4-967]). However, some SGAs have been associated with various adverse metabolic effects, such as glucose dysregulation, dyslipidemia and significant weight gain ([@b21-ndt-4-967]; [@b8-ndt-4-967]; [@b4-ndt-4-967]; [@b56-ndt-4-967]). Together with hypertension, these abnormalities comprise metabolic syndrome ([@b9-ndt-4-967]), which is associated with an increased risk for diabetes and coronary heart disease (CHD) ([@b28-ndt-4-967]; [@b46-ndt-4-967]).

In addition to the increased risk for metabolic syndrome with certain SGAs, patients with schizophrenia already have increased risk factors for CHD, eg, smoking ([@b21-ndt-4-967]; [@b8-ndt-4-967]) and obesity ([@b4-ndt-4-967]; [@b56-ndt-4-967]). Moreover, patients with schizophrenia have a 5-fold higher risk of myocardial infarction than the general population ([@b10-ndt-4-967]) and are also at increased risk for diabetes, independent of medication usage ([@b9-ndt-4-967]; [@b59-ndt-4-967]). Recent findings from the CATIE study report a 40% prevalence of metabolic syndrome in patients with schizophrenia ([@b38-ndt-4-967]). Consequently, the metabolic profiles of SGAs are important when considering treatment options for this patient population ([@b59-ndt-4-967]). Given the significant social and economic costs associated with treating patients with diabetes ([@b34-ndt-4-967]; [@b35-ndt-4-967]; [@b45-ndt-4-967]), existing differences in metabolic profiles must be considered when choosing a pharmacological intervention for schizophrenia ([@b40-ndt-4-967]).

In Italy the average yearly total cost of a type 2 diabetes patient is about €3,136 per patient, while the estimated cost of the whole type 2 diabetes population is about €5,423 million. Direct costs account for 95.5% of the total. On the whole, they correspond to 6.65% of the total health care expenditure (public plus private) ([@b34-ndt-4-967], [@b35-ndt-4-967]). The substantial economic and social impacts of the disease result from high mortality rates (particularly among young adults), loss of employment, homelessness, family burden, and excessive use of inpatient health services, social services and housing services ([@b16-ndt-4-967]; [@b25-ndt-4-967]; [@b10-ndt-4-967]; [@b12-ndt-4-967]).

The SGA aripiprazole has been shown to have clinical efficacy similar to that of other SGAs and FGAs ([@b24-ndt-4-967]; [@b36-ndt-4-967]; [@b39-ndt-4-967]). Moreover, aripiprazole has not been associated with the same degree of EPS observed with the older FGA haloperidol ([@b24-ndt-4-967]; [@b36-ndt-4-967]; [@b3-ndt-4-967]) or with weight gain observed with many of the other SGAs ([@b39-ndt-4-967]; [@b1-ndt-4-967]).

The objective of this analysis was to conduct an economic evaluation of aripiprazole versus olanzapine for the treatment of schizophrenia in the Italian setting from a third-party payer perspective (Servizio Sanitario Nazionale -- National Health Service \[NHS\]). Specifically, assuming equal clinical efficacy between the two agents, we will evaluate the pharmacotherapy costs of treatment for schizophrenia and the medical costs of treating adverse metabolic effects (eg, dyslipidemia, diabetes).

Methods
=======

The model is developed to show the potential short-run and long-run cost savings in terms of incidence of metabolic syndrome and a lower risk of diabetes generated for a simulated cohort of 1000 patients with schizophrenia when treated with aripiprazole compared with olanzapine. These data were elaborated from a 26-week, multicenter, double-blind study comparing a flexible dose of aripiprazole 15--30 mg/day (n = 155) with a flexible dose of olanzapine 10--20 mg/day (n = 159) on changes in weight and efficacy in the management of schizophrenia ([@b39-ndt-4-967]). The results of this study demonstrated that efficacy was comparable between treatment arms, as evidenced by sustained improvement in Positive and Negative Syndrome Scale (PANSS) scores, Clinical Global Impressions -- Improvement scores, and in responder rates throughout the study. A sub-sample of patients (314 out of 317) from this trial ([@b39-ndt-4-967]) who had complete metabolic data in addition to the weight data was used to assess metabolic syndrome changes during the 26-week in-trial therapy period, and to model the risk of diabetes in the ensuing 5 years after the formal trial period.

Metabolic syndrome was defined as the presence or clinically meaningful exacerbation of three of five National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III risk factors ([@b42-ndt-4-967]). In addition, a combination definition that consisted of NCEP ATP III criteria and the clinically meaningful percentage change from baseline of those criteria were established ([Table 1](#t1-ndt-4-967){ref-type="table"}). Given that waist circumferences for most patients enrolled in the study were unavailable, the working definition involved the use of body mass index (BMI) rather than waist circumference to define abdominal obesity. This is supported by several metabolic studies in which BMI served as a surrogate for waist circumference ([@b45-ndt-4-967]; [@b49-ndt-4-967]; [@b13-ndt-4-967]) and by a demonstrated positive correlation between these measures in another study ([@b30-ndt-4-967]).

Model structure
---------------

In this model, treatment with either aripiprazole or olanzapine was assessed for metabolic disturbances over the 26 weeks of the study, and simulated to provide a comparison of estimated incidence rates of diabetes over 5 years, with corresponding estimated direct costs of care ([Figure 1](#f1-ndt-4-967){ref-type="fig"}). A comparative economic evaluation was conducted based on aripiprazole and olanzapine having comparable efficacy. Post-hoc analyses of PANSS scores in the present study support this assumption. Besides assuming equal efficacy between aripiprazole and olanzapine, it was assumed that compliance with therapy was not affected by the occurrence of adverse events (AEs), including weight gain. Furthermore, the estimated risk for diabetes was based on changes from baseline to week 26 observed during the 26-week study period.

Estimation of diabetes incidence
--------------------------------

The impact of therapy on the risk factors associated with the development of diabetes and its projected incidence were calculated for aripiprazole and olanzapine using a risk-prediction model developed by [@b53-ndt-4-967]. This multivariate model used data from the San Antonio Heart Study ([@b6-ndt-4-967]) to predict the risk of developing type 2 diabetes in 7.5 years. Variables in the model include patient characteristics (age, sex, ethnicity, and family history of diabetes) and laboratory values (fasting glucose, HDL, BMI, and systolic blood pressure). The authors found this risk-prediction model to be a viable alternative to the glucose tolerance test in predicting the risk of diabetes.

The current study incorporated patient data from the clinical study of [@b39-ndt-4-967] into the diabetes risk-prediction model developed by [@b44-ndt-4-967]. The expected incidence of diabetes was projected for a 5-year period, but it was assumed that the measures affecting the outcomes of interest would not change further after week 26; it is actually likely that a medication that causes a metabolic parameter, such as body weight, to change over 26 weeks will continue to do so beyond that period ([@b41-ndt-4-967]; [@b20-ndt-4-967]).

To correct for any nominal differences in the variables at baseline between treatment arms, an analysis adjusting for baseline risk (analysis of covariance \[ANCOVA\]; proc. GLM, SAS version 8.1; SAS Institute, Cary, NC) was performed. After calculating the risk at 7.5 years (*r*), annual risk levels at time (*t*) between 0 and 5 years were approximated according to the following equation:
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Estimation of costs
-------------------

Economic analysis was conducted from the third-party payer perspective (NHS) by evaluation of the pharmacotherapy costs of treating schizophrenia and the direct costs of treating metabolic AEs and/or diabetes. Resource utilization and costs were derived from the clinical study and from published data ([@b34-ndt-4-967]; [@b35-ndt-4-967]). An annual discount rate of 3% was used to discount the annual costs and benefits beyond the first year of assessment.

Unit costs for antipsychotic drug were obtained from the [@b32-ndt-4-967] and were applied to the dosages/strengths used. The daily costs were used to calculate drug costs for 26 weeks of therapy ([Table 2](#t2-ndt-4-967){ref-type="table"}). The cost of diagnosing and treating metabolic syndrome was estimated by assigning unit resource costs to physician visits, laboratory tests (eg, blood glucose and lipids), and drugs for treating hyperlipidemia (eg, statins, fibrates, niacin), hyperglycemia (oral antidiabetic agents) and hypertension (antihypertensives). The costs of diagnosing and treating the metabolic syndrome were estimated by assigning unit resource costs and drug costs ([Table 3](#t3-ndt-4-967){ref-type="table"}).

The cost of initializing treatment for metabolic syndrome, including office visits, tests and medications, was calculated for all patients. The direct cost estimate of treating diabetes was calculated according to the 1997 American Diabetes Association published estimates on medical treatment for patient with type 2 diabetes mellitus ([@b15-ndt-4-967]; [@b51-ndt-4-967]; [@b54-ndt-4-967], [@b55-ndt-4-967]; [@b2-ndt-4-967]); these data were modified taking into account the Italian CODE Study and the BRESCIA Study ([@b34-ndt-4-967], [@b35-ndt-4-967]; [@b50-ndt-4-967]), which included inpatient and outpatient visits (including home health, hospice, and nursing home care and emergency room visits), tests, diagnostic procedures, other health services and diabetic drug treatment in Italy. The ISTAT medical care component of the Consumer Price Index was applied to approximate the time frame from which the current data originate at year 2007 ([@b22-ndt-4-967]).

Statistical analysis
--------------------

Kaplan--Meier survival analysis was performed to estimate the cumulative incidence of metabolic syndrome (using the modified definition described in [Table 1](#t1-ndt-4-967){ref-type="table"}) over the course of the 26-week study. The log-rank test was used to test the difference between the survival functions. The risk for diabetes was estimated based on vital signs, laboratory values, and demographic data collected at the baseline and at week 26 visits using a validated, general population risk model developed by [@b53-ndt-4-967]. To correct for any nominal differences in these factors between treatment groups at baseline, ANCOVA was performed to adjust for baseline risk. After calculating the risk at 7.5 years, annual risk levels between 0 and 5 years were approximated for each treatment group ([@b53-ndt-4-967]).

Sensitivity analysis
--------------------

Sensitivity analysis was performed according to clinical study (CT)-based and the RW dose regimens. Because this was a CT-based economic evaluation, the distributions of patients on different dose strengths (15--30 mg for aripiprazole, 10--20 mg for olanzapine) during the 26-week study were used in this economic evaluation. This enabled us to estimate a plausible range of costs for the simulated patient sample observed in the study, based on CT dose regimens and on those reflecting RW regimens observed with patients in these dose ranges.

Results
=======

The patient groups modeled had similar baseline demographic and metabolic characteristics ([Table 4](#t4-ndt-4-967){ref-type="table"}). Based on a Kaplan--Meier survival analysis, aripiprazole was associated with a lower incidence of metabolic syndrome and a delayed onset of development of metabolic syndrome compared with olanzapine ([Figure 2](#f2-ndt-4-967){ref-type="fig"}). The log-rank test found a statistically significant difference (p = 0.011) between the two incidence functions with an estimated hazard ratio for aripiprazole versus olanzapine of 0.31 (95% confidence interval \[95% CI\]; 0.12, 0.77). At 26 weeks, the estimated cumulative incidence rates of new or worsening metabolic syndrome were 20.9% (± 7.8% \[95% CI\]) for olanzapine and 9.2% (± 5.5% \[95% CI\]) for aripiprazole.

Based on the estimated incidence rates, costs associated with the treatment of metabolic syndrome and pharmacotherapy for schizophrenia were determined. Compared with olanzapine, aripiprazole use was found to be a dominant cost-saving strategy for treating schizophrenia. Based on the estimated absolute risk reduction of 18.4%, aripiprazole use instead of olanzapine in a simulated cohort of 1000 patients resulted in the avoidance of 184 occurrences -- new or worsening cases -- of metabolic syndrome after the 26 weeks of therapy until 1 year; this risk reduction reflects the metabolic characteristics seen for each drug in clinical studies and observational studies ([@b43-ndt-4-967]). Avoidance of these cases would contribute to a cost savings of €2.53 per patient and a total savings of approximately €465.52 ([Table 5](#t5-ndt-4-967){ref-type="table"}).

When considering diabetes prevention, aripiprazole was also a dominant cost-saving strategy. In the simulated cohort of 1000 patients, the values with aripiprazole for 26 weeks showed the avoidance of 34 events of diabetes over 5 years (18 in discounted scenario), resulting in a total cost savings of €1,926.65 (€966.77 in discounted scenario). In these scenarios, the cost savings reflect lower treatment costs of metabolic syndrome and diabetes, and lower aripiprazole acquisition costs.

Discussion
==========

These results highlight the medical and economic benefits from maintenance therapy with aripiprazole compared with olanzapine, reflected by the reduced incidences of metabolic syndrome and diabetes, and lower total costs associated with aripiprazole treatment. Even though the efficacy of aripiprazole and olanzapine was found to be comparable in the original clinical trial ([@b39-ndt-4-967]), this analysis found aripiprazole to be more cost effective than olanzapine when metabolic side effects and their related treatment costs were accounted for. In this study, treatment costs (attributed to fewer metabolic AEs) and drug acquisition costs were lower with aripiprazole use.

The present analysis also found reduced incidence of new and worsening metabolic syndrome in patients treated with aripiprazole than those treated with olanzapine. The consequent projected risk for diabetes was also lower in aripiprazole-treated patients. These results are consistent with those of other studies in which olanzapine is associated with an increased attributable risk for diabetes over background rates ([@b43-ndt-4-967]; [@b26-ndt-4-967]; [@b31-ndt-4-967]; [@b29-ndt-4-967]). In contrast, the incidence of metabolic syndrome and the projected risk for diabetes are not significantly different between aripiprazole and placebo ([@b58-ndt-4-967];L'Italien et al 2006). This suggests that the increased risk for diabetes projected in this study for patients on olanzapine may be due to some intrinsic quality of that drug, whereas aripiprazole-treated patients showed an incidence similar to the background rate for diabetes among patients with schizophrenia in general. Risk projections for diabetes presented previously were based on changes in metabolic parameters observed over 26 weeks ([@b39-ndt-4-967]) and were not extrapolated beyond that period, probably underestimating the full long-term benefit of aripiprazole. However, it must be pointed out that McQuade's study is a large comparative atypical study designed to show non-inferiority of aripiprazole versus olanzapine in over 700 subjects. In contrast with these results, we have to note that, according to a study by McCue (2007), olanzapine was significantly more effective than aripiprazole: the relevance of these results must be considered in the context of certain limitations of our analysis.

In our simulation, BMI was used as reference parameter to assess the impact of metabolic syndrome and conversion to waist circumference was performed. It must be noted that the relationship between these two adiposity measures may not be so straightforward, as shown by Faulkner et al (2007), who developed a schizophrenia-specific conversion system from BMI to abnormal waist. The etiology of the increased prevalence of type 2 diabetes mellitus in psychiatric disorders is uncertain, and although it might be due to the weight gain associated with atypical antipsychotic agents, this hypothesis should be regarded cautiously, especially in light of the fact that schizophrenia may be an independent risk factor for diabetes mellitus ([@b47-ndt-4-967]; [@b14-ndt-4-967]). Consequently, our simulation should probably be updated based on these considerations, though more robust clinical trials would be necessary to gain more insights into this question.

Estimated costs of therapy with both agents assumed 100% compliance and an unchanged average daily dose for 5 years; chronic diseases associated with metabolic syndrome other than diabetes were not included in the cost calculations. Finally, the doses used do not reflect RW regimens of the two drugs in clinical practice; treatment with RW doses might lead to different risks for metabolic consequences, although published studies showing a link between diabetes onset and RW use of olanzapine do not report a dose-dependent risk ([@b26-ndt-4-967]; [@b52-ndt-4-967]). Nonetheless, the application of an RW dose would probably result in higher cost savings with aripiprazole, assuming a dose-independent AE profile, as RW dosing is increased relatively more for olanzapine than for aripiprazole ([@b7-ndt-4-967]), resulting in a larger increase in medication cost for olanzapine. It must be pointed out that the model used in this study has a limitation that depends on the lack of information on aripiprazole's behavior in terms of long-term treatment. If aripiprazole clinical efficacy is related to an increase in RW dosing over time that is proportionally superior to that of olanzapine, the results of this study could be reversed, with olanzapine being more cost-effective. On the contrary, if aripiprazole use beyond the period considered does not increase more than or is the same as that of olanzapine, our economic analysis would prove aripoprazole's advantage over olanzapine from a medical and economic point of view. To be able to confirm either of the two hypotheses, a drug-utilization study for aripiprazole would be necessary.

Because of the difficulty in estimating the costs associated with weight gain (eg, use of weight-lowering adjunct therapy) from the payer's perspective, these costs were not considered in this economic evaluation. However, weight gain and the indirect costs associated with it are certainly not inconsequential. Moreover, weight gain has a potential impact on metabolic syndrome, triglyceride levels, hypertension, CHD, stroke, and diabetes ([@b27-ndt-4-967]; [@b5-ndt-4-967]). In addition to these health risks among patients with schizophrenia, excessive weight gain can also cause quality-of-life impairment, increased relapse associated with non-compliance, and social withdrawal because of the stigma of obesity ([@b27-ndt-4-967]).

The relevance of these results must be considered in the context of certain limitations. It should be emphasized that this work represents a cost-consequence analysis. The comparative study from which the incidence of metabolic syndrome was derived demonstrated a reduced incidence of new or worsening metabolic syndrome with aripiprazole than olanzapine. If metabolic syndrome was not prevented or treated, it was assumed that diabetes would develop in the projected number of patients. Finally, since the data used to develop our model were obtained from a study carried out in the US, one may doubt how representative these data might be for European patients (eg, different ethnicities). Nevertheless, this is a first attempt and may be regarded as a first step for developing studies more targeted to the European context.

The estimated avoidance of diabetes is a projection that must be confirmed in a prospective long-term study. Another limitation is that the issue of persistence was not included in this model. The possibility of discontinuing or switching drugs -- events that could possibly change the predicted risk of metabolic syndrome or diabetes -- was not considered in this analysis. In conclusion, the use of aripiprazole can avoid incidences of metabolic syndrome and potentially diabetes, thereby improving patient health and lowering healthcare costs; the present data suggest that aripiprazole may be a beneficial and cost-effective alternative to olanzapine, and more appropriate for patients at greatest risk of metabolic complications.
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###### 

Metabolic syndrome definitions

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Adult Treatment Panel III Definition ([@b9-ndt-4-967])          Modified Definition
  --------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------
  Waist circumference ≥40 inches (male) and ≥35 inches (female)   \>7% increases in BMI from baseline AND BMI \>25 kg/m^2^[\*](#tfn1-ndt-4-967){ref-type="table-fn"}

  HDL-C \<40 mg/dL (male) and \<50 mg/dL (female)                 \>15% decrease in HDL-C from baseline AND HDL-C \<40 mg/dL[†](#tfn2-ndt-4-967){ref-type="table-fn"}

  DBP ≥85 mmHg or SBP ≥130 mmHg                                   ≥8 mmHg increase in DBP from baseline AND DBP ≥85 mmHg\
                                                                  OR

                                                                  ≥12 mmHg increase from baseline in SBP AND SBP ≥130 mmHg[‡](#tfn3-ndt-4-967){ref-type="table-fn"}

  Fasting triglycerides ≥150 mg/dL                                ≥15% increase from baseline from baseline in fasting triglycerides AND fasting triglycerides ≥150 mg/dL

  Fasting plasma glucose ≥110 mg/dL                               ≥20% increase from baseline in fasting plasma glucose AND fasting plasma glucose ≥110 mg/dL[§](#tfn4-ndt-4-967){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI was used rather than abdominal circumference because both are good predictors of metabolic outcomes and the former was directly related to the primary endpoint of the study. Waist circumference was not always available.

A simplification was made to consider values \<40 mg/dL for men and women.

8 mmHg and 12 mmHg constitute the standard deviations for DBP and SBP measurements, respectively. Hence, any changes beyond these values may be considered true elevations in blood pressure.

Some patients did not have a fasting blood glucose measurement at baseline. For those patients, non-fasting values were used at baseline and subsequent visits.

**Abbreviations:** BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; DBP, diastolic blood pressure; SBP, systolic blood pressure.

###### 

Direct medical costs for management of metabolic syndrome

  Cost type                                        EUR €         Comment and source
  --------------------- -------------------------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  Aripiprazole, 15 mg                              €5.02         [@b32-ndt-4-967]
  Olanzapine, 10 mg                                €5.02         [@b32-ndt-4-967]
  Unit resource costs   Physician visits           €23.00        2006 National Tariff Nomenclator, Health Ministry
                        Glucose tests              €1.29         2006 National Tariff Nomenclator, Health Ministry
                        Lipid test                 €3.15         Includes HDL and triglycerides, 2006 National Tariff Nomenclator, Health Ministry
  Drug costs            Hyperlipidemic agents      See comment   Weighted average price/day for statins (€0.79), fibrates (€0.52) or niacin (€1.70) using weights of 0.4, 0.3 and 0.3, respectively (OSMED 2007)
                        Oral hypoglycemic agents   €0.20         OSMED, 2007
                        Antihypertensives          €0.26         OSMED, 2007

**Abbreviations:** HDL, high-density lipoprotein.

###### 

Resource utilization: type II diabetes

  Diabetic treatment               Units              Unit cost                  Value       Source                                                                                    Comments
  -------------------------------- ------------------ -------------------------- ----------- ----------------------------------------------------------------------------------------- ----------------
  **Hospitalizations**             ALOS/No of hosps   Per diem/DRG cost          €4,774.13   DM 12/09/2006                                                                             DRG 294
   Emergency room visits           No of visits       Cost per visit             €34.50      DM 12/09/2006                                                                             Cod 89.7 + 50%
  **Physician visits**                                                                                                                                                                 
   Physician visit                 No of visits       Cost per consult           €13.03      [@b34-ndt-4-967] and [@b35-ndt-4-967]                                                     
   Hospital outpatient visit       No of visits       Cost per consult           €23.00      DM 12/09/2006                                                                             
  **Test/Diagnostic procedures**                                                                                                                                                       
   Oral glucose test               No of tests        Cost per test              €30.57      DM 12/09/2006                                                                             Cod 90.28.5
   Glycosylated Hemoglobin         No of tests        Cost per test              €10.59      DM 12/09/2006                                                                             Cod 90.28.1
   Urinalysis                      No of tests        Cost per test              €2.07       DM 12/09/2006                                                                             Cod 90.44.3
   Vision test                     No of tests        Cost per test              €7.75       DM 12/09/2006                                                                             Cod 95.09.1
  **Other health care services**                                                                                                                                                       
   Home health care                No of visits       Cost per visit             €46.48      DM 12/09/2006                                                                             Cod 89.07
   Hospice care                    No of days         Cost per visit             €201.42     Deliberation of the Regional Council of Lombardy of 13/12/06 and nr. 4239 of 28/02/2007   
   Nursing home care               No of days         Cost per visit             €166.67     Lombardy Region, Hospital of Busto Arsizio, Varese                                        
  **Drug therapy**                                                                                                                                                                     
   Sulfonylureas                   No of treatments   Cost per treated patient   €0.1831     [@b34-ndt-4-967] and [@b35-ndt-4-967]                                                     €/die
   Biguanides                      No of treatments   Cost per treated patient   €0.0001     [@b34-ndt-4-967] and [@b35-ndt-4-967]                                                     €/die
   Alpha-glucosidase inhibitors    No of treatments   Cost per treated patient   €0.681      [@b34-ndt-4-967] and [@b35-ndt-4-967]                                                     €/die
   Thiazodilinediones              No of treatments   Cost per treated patient   €2.071      [@b34-ndt-4-967] and [@b35-ndt-4-967]                                                     €/die
   Meglitinides                    No of treatments   Cost per treated patient   €0.036      [@b34-ndt-4-967] and [@b35-ndt-4-967]                                                     €/die
   Insulin                         No of treatments   Cost per treated patient   €0.892      [@b34-ndt-4-967] and [@b35-ndt-4-967]                                                     €/die

**Abbreviations:** ALOS, average length of stay; DM, Decreto Ministeriale \[Ministerial Decree\]; Cod, code; DRG, diagnosis-related group.

###### 

Characteristics of patients observed at baseline and change at Week 26 (LOCF) in the clinical study

                                                 Aripiprazole 15--30 mg/day (n = 155)[a](#tfn8-ndt-4-967){ref-type="table-fn"}   Olanzapine 10--20 mg/day (n = 59)[a](#tfn8-ndt-4-967){ref-type="table-fn"}                                  
  ---------------------------------------- ----- ------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ----- ---------------- ------- ---------
  Mean age, y (SE)                         155   38.72 (0.86)                                                                    --                                                                           159   38.13 (0.88)     --      --
  Male, n (%)                              155   113 (73%)                                                                       --                                                                           159   113 (71%)        --      --
  Mean weight, kg (SE)                     136   80.82 (1.84)                                                                    −0.86                                                                        138   80.42 (1.85)     3.35    \<0.001
  Mean body mass index, kg/m^2^ (SE)       156   27.6 (0.5)                                                                      −0.10                                                                        161   27.7 (0.6)       0.8     \<0.001
  Mean fasting serum glucose, mg/dL (SE)   107   89.88 (2.02)                                                                    2.68                                                                         115   91.68 (1.95)     3.22    NS
  Mean HbA1c, % (SE)                       144   5.50 (0.06)                                                                     0.02                                                                         145   5.56 (0.06)      0.11    NS
  Mean total cholesterol, mg/dL (SE)       108   184.10 (4.06)                                                                   −3.47                                                                        115   184.64 (3.94)    9.18    0.009
  Mean LDL-C, mg/dL (SE)                   108   107.83 (3.47)                                                                   −1.43                                                                        114   110.33 (3.38)    5.04    NS
  Mean HDL-C, mg/dL (SE)                   108   44.00 (1.17)                                                                    2.7                                                                          114   43.69 (1.14)     −0.37   0.019
  Mean fasting triglycerides, mg/dL (SE)   108   162.44 (10.68)                                                                  −20.20                                                                       114   159.36 (10.39)   17.07   0.012

Not all measures were available for every patient.

**Abbreviations:** LOCF, last observation carried forward; NS, non-significant; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SE, standard error.

###### 

Results: Direct medical costs and metabolic adverse effects avoided from over 26 weeks of aripiprazole therapy (model results based on [@b39-ndt-4-967]) -- Base case scenario

                                                      Outcomes                                              
  ----------------- --------------------------------- ----------- ----------- --------- ------------- ----- ------------
  26-week therapy   Metabolic syndrome                €1,619.36   €1,621.89   −€2.53    Cost saving   184   −€13.79
  5 years           Type 2 diabetes (undiscounted)    €7,936.55   €7,993.41   −€56.86   Cost saving   34    −€1,678.18
  5 years           Type 2 diabetes (discounted 3%)   €7,315.83   €7,368.42   −€52.59   Cost saving   18    −€2,860.52

Includes cost of antipsychotic therapy and the costs of treating metabolic syndrome and diabetes for the patients with these adverse effects.

###### 

Sensitivity analysis: dose die increasing for aripiprazole and olanzapine

                                                      Outcomes                                                          
  ----------------- --------------------------------- ---------------------------- -------------------------- --------- -------------
  26-week therapy   Metabolic syndrome                €2,428.03                    €2,430.80                  −€2.76    Cost saving
  5 years           Type 2 diabetes (undiscounted)    €11,830.19                   €11,888.16                 −€57.97   Cost saving
  5 years           Type 2 diabetes (discounted 3%)   €10,904.86                   €10,958.47                 −€53.61   Cost saving
                                                      **Aripiprazole 30 mg/die**   **Olanzapine 20 mg/die**             
  26-week therapy   Metabolic syndrome                €3,236.71                    €3,239.48                  −€2.76    Cost saving
  5 years           Type 2 diabetes (undiscounted)    €15,723.83                   €15,781.80                 −€57.97   Cost saving
  5 years           Type 2 diabetes (discounted 3%)   €14,493.88                   €14,547.49                 −€53.61   Cost saving
